519 results on '"Scher, Jose U."'
Search Results
102. A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health
103. Key opinion leaders — a critical perspective
104. Auto-deconvolution and molecular networking of gas chromatography–mass spectrometry data
105. Contributors
106. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis
107. Neutrophils I
108. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS–CoV‐2 Vaccination.
109. Does biologic therapy impact the development of PsA among patients with psoriasis?
110. Neutrophils and Eosinophils
111. Periodontal disease, Porphyromonas gingivalis, and rheumatoid arthritis: what triggers autoimmunity and clinical disease?
112. The microbiome and rheumatoid arthritis
113. 24 - The microbiome in rheumatic diseases
114. Prevalence, Predictors, and Disease Activity of Sacroiliitis Among Patients with Crohn’s Disease
115. Response to: ‘Microbiome in Sjögren’s syndrome: here we are’ by van der Meulen et al
116. Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York
117. The microbiome in rheumatology: Where are we and where should we go?
118. Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2018 Annual Meeting Summary
119. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
120. Algorithmic Learning for Auto-deconvolution of GC-MS Data to Enable Molecular Networking within GNPS
121. Methotrexate-Induced Shifts in the Human Gut Microbiome Decrease Immune Activation
122. Methotrexate Impacts Conserved Pathways in Diverse Human Gut Bacteria Leading to Decreased Host Immune Activation
123. Interleukin 1 receptor antagonist (IL1RN) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease
124. Distinct Polysaccharide Utilization Profiles of Human Intestinal Prevotella copri Isolates
125. Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease
126. 816 The Prevalence and Clinical Associations of Sacroiliitis in Crohn’s Disease Using a Standardized Magnetic Resonance Scoring System
127. The Anti-Inflammatory Effects of Prostaglandins
128. 15d-PGJ 2: The anti-inflammatory prostaglandin?
129. Erratum to: Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis
130. Prevalence, Predictors, and Disease Activity of Sacroiliitis Among Patients with Crohn's Disease.
131. A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health.
132. Supplemental Material, Appendix_4_Study_Selection_Process - 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
133. Supplemental Material, Singh_ART40726_Supplementary_Appendix_1_Methods - 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
134. Distinct polysaccharide growth profiles of human intestinalPrevotella copriisolates
135. OP0108 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY
136. Perturbation of the human gut microbiome by a non-antibiotic drug contributes to the resolution of autoimmune disease
137. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
138. Microbiota‐Dependent Involvement of Th17 Cells in Murine Models of Inflammatory Arthritis
139. COVID‐19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease‐Modifying Antirheumatic Drugs on Clinical Outcomes.
140. Leveraging the United States Epicenter to Provide Insights on COVID‐19 in Patients With Systemic Lupus Erythematosus.
141. Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease.
142. Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response.
143. Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1.
144. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study.
145. Interleukin 1 receptor antagonist ( ) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease.
146. Strategies to Improve Outcomes in Psoriatic Arthritis.
147. The Microbiome in Psoriasis and Psoriatic Arthritis: Joints
148. Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis
149. Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis
150. Human microbiome, infections, and rheumatic disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.